ABT
ABBOTT LABORATORIESCompliant · 92/100
Sector: Healthcare · Industry: Drug Manufacturers - General · Data as of 2026-02-20
Screening standard
The evidence
| Test | Figure | Limit | Source |
|---|---|---|---|
| Passed: Business activityBusiness activity is compliant. | compliant | ||
| Passed: Debt vs. market capinterest-bearing debt / market cap = 6.28% (< 33% limit). | 6.28% | < 33.00% | |
| Passed: Interest income vs. revenueinterest income / total revenue = 0.69% (< 5% limit). | 0.69% | < 5.00% | |
| Passed: Cash & interest-bearing assets vs. market cap(cash + interest-bearing securities) / market cap = 4.34% (< 33% limit). | 4.34% | < 33.00% |
Every number, sourced
Figures read directly from SEC EDGAR XBRL facts. Don't trust us — verify.
| Figure | Value | Source |
|---|---|---|
| Total revenueRevenue from contract with customer excluding assessed tax | $44.3B | |
| Interest-bearing debtLong term debt | $12.9B | |
| Cash & interest-bearing securities2 components | $8.9B | |
| Interest incomeInvestment income interest | $308.0M | |
| Total assetsAssets | $86.7B | |
| ReceivablesAccounts receivable net current | $7.9B | |
| Shares outstandingEntity common stock shares outstanding | 1.7B shares | |
| Priceyahoo:24mo-trailing-avg | $118.152 |
Dividend purification
Est. 0.69% of dividends should be purified.
Price
Values & Controversies
Separate from the shariah verdict above — always.
No flags. This company isn't on the BNC (Boycott National Committee) priority or divestment lists, or any grassroots BDS-supported campaign we line.